LYVE1 Antibodies

Structure of LYVE1

LYVE1 is a type I transmembrane glycoprotein with a molecular weight of approximately 41-43 kDa. Its molecular weight varies slightly among different species due to differences in the degree of glycosylation.

This protein is composed of 322 amino acids, and its core structural feature is a Link module located in the extracellular region (similar to the domain of CD44), which is responsible for specifically recognizing and binding to hyaluronic acid. Its transmembrane domain anchors the protein to the cell membrane, while the shorter intracellular tail region is involved in signal transduction. The three-dimensional structure of the Link module forms a specific fold, constituting the hyaluronic acid binding pocket. This structural basis determines the specificity and function of its ligand binding.

Fig. 1 X-ray crystallographic structures of unbound mLYVE-1 and hLYVE-1 HABDs.¹

Key structural properties of LYVE1:

• Extracellular Link module domain (CD44-like folding)
• Specific hyaluronic acid binding pocket
• Type I single transmembrane anchoring structure

Functions of LYVE1

The main function of LYVE1 (lymphatic endothelial hyaluronic acid receptor 1) is to mediate the binding of lymphatic endothelial cells to hyaluronic acid, thereby regulating lymphangiogenesis and immune cell transport. Meanwhile, it is also involved in a variety of pathophysiological processes, including tumor metastasis and inflammatory responses.

Compared with hyaluronic acid receptors such as CD44, LYVE1 has a higher affinity for hyaluronic acid and is more specific. Its expression is almost limited to the lymphatic endothelium, making it a key molecular marker for studying lymphatic system function and tumor lymphatic metastasis.

Applications of LYVE1 and LYVE1 Antibody in Literature

1. Hog, Pauline, et al. "Prostaglandin e2 boosts the hyaluronan-mediated increase in inflammatory response to lipopolysaccharide by enhancing lyve1 expression." Biology 12.11 (2023): 1441. https://doi.org/10.3390/biology12111441  

Research has found that the hyaluronic acid receptor Lyve1 on the surface of macrophages plays a key role in the resolution of inflammation. Prostaglandin E2 enhances the expression of Lyve1 through the EP2 receptor signaling pathway, enabling this macrophage subpopulation to respond synergistically to the inflammatory stimulation of lipopolysaccharide and low-molecular-weight hyaluronic acid, and integrate extracellular matrix signals with inflammatory responses.

2. Anstee, Joanne E., et al. "LYVE-1+ macrophages form a collaborative CCR5-dependent perivascular niche that influences chemotherapy responses in murine breast cancer." Developmental cell 58.17 (2023): 1548-1561. https://doi.org/10.1016/j.devcel.2023.06.006

Studies have found that in the spontaneous breast cancer model, tumor-associated macrophages expressing LYVE-1 are induced by IL-6 to form paravicular "nest" structures, which synergically inhibit CD8⁺T cell infiltration through CCR5 signaling and lead to chemotherapy resistance. Blocking this subset can enhance anti-tumor immunity and the efficacy of chemotherapy.

3. Feng, Zhenzhen, and Jiyuan Wu. "hsa_circ_0129047 Upregulates LYVE1 to Inhibit Hepatocellular Carcinoma Progression by Sponging miR‐492." Disease Markers 2023.1 (2023): 6978234. https://doi.org/10.1155/2023/6978234 

Studies have found that the circular RNA circ_0129047 is down-regulated in liver cancer. It inhibits tumor cell proliferation and metastasis by adsorbing miR-492 and relieving its inhibition of the target gene LYVE1, suggesting that this axis is expected to become a new therapeutic target for liver cancer.

4. Turiel, Guillermo, et al. "Single-cell compendium of muscle microenvironment in peripheral artery disease reveals altered endothelial diversity and LYVE1+ macrophage activation." Nature Cardiovascular Research (2025): 1-20. https://doi.org/10.1038/s44161-025-00709-y 

This study found through single-cell sequencing that LYVE1hiMHCIIlow macrophages were dominant in the skeletal muscle of patients with lower extremity arterial disease and showed pro-inflammatory transformation. Endothelial cells influence their polarization through signals, providing new evidence for targeted therapy.

5. Liu, Jing, et al. "Serum soluble LYVE1 is a promising non-invasive biomarker of renal fibrosis: a population-based retrospective cross-sectional study." Immunologic Research 72.3 (2024): 476-489. https://doi.org/10.1007/s12026-023-09448-3

The article indicates that the level of serum soluble LYVE1 is positively correlated with the degree of renal fibrosis. After being incorporated into the diagnostic model, the model's predictive ability for moderate to severe and severe renal fibrosis was significantly enhanced, and it is expected to become a novel biomarker for non-invasive diagnosis of renal fibrosis.

Creative Biolabs: LYVE1 Antibodies for Research

Creative Biolabs specializes in the production of high-quality LYVE1 antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom LYVE1 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our LYVE1 antibodies, custom preparations, or technical support, contact us at email.